Mesenchymal tumor subpopulations secrete pro-tumorigenic cytokines and promote treatment resistance 1-4 . This phenomenon has been implicated in chemorefractory small cell lung cancer and resistance to targeted therapies 5-8 , but remains incompletely defined. Here, we identify a subclass of endogenous retroviruses (ERVs) that engages innate immune signaling in these cells. Stimulated 3 prime antisense retroviral coding sequences (SPARCS) are oriented inversely in 3′ untranslated regions of specific genes enriched for regulation by STAT1 and EZH2. Derepression of these loci results in double-stranded RNA generation following IFN-γ exposure due to bi-directional transcription from the STAT1-activated gene promoter and the 5′ long terminal repeat of the antisense ERV. Engagement of MAVS and STING activates downstream TBK1, IRF3, and STAT1 signaling, sustaining a positive feedback loop.
Mesenchymal tumor subpopulations secrete pro-tumorigenic cytokines and promote treatment resistance [1] [2] [3] [4] . This phenomenon has been implicated in chemorefractory small cell lung cancer and resistance to targeted therapies 5-8 , but remains incompletely defined. Here, we identify a subclass of endogenous retroviruses (ERVs) that engages innate immune signaling in these cells. Stimulated 3 prime antisense retroviral coding sequences (SPARCS) are oriented inversely in 3′ untranslated regions of specific genes enriched for regulation by STAT1 and EZH2. Derepression of these loci results in double-stranded RNA generation following IFN-γ exposure due to bi-directional transcription from the STAT1-activated gene promoter and the 5′ long terminal repeat of the antisense ERV. Engagement of MAVS and STING activates downstream TBK1, IRF3, and STAT1 signaling, sustaining a positive feedback loop. SPARCS induction in human tumors is tightly associated with major histocompatibility complex class 1 expression, mesenchymal markers, and downregulation of chromatin modifying enzymes, including EZH2. Analysis of cell lines with high inducible SPARCS expression reveals strong association with an AXL/MET-positive mesenchymal cell state. While SPARCS-high tumors are immune infiltrated, they also exhibit multiple features of an immune-suppressed microenviroment. Together, these data unveil a subclass of ERVs whose derepression triggers pathologic innate immune signaling in cancer, with important implications for cancer immunotherapy.
Resistant chemorefractory small-cell lung cancer (SCLC) undergoes a mesenchymal state switch induced by RAS/MET signaling or chemotherapy (for example, H69M or H69AR subpopulations derived from H69 cell line) ( Supplementary Fig. 1a ) 9, 10 . We noted enhanced innate immune and RAS signaling in H69M cells, including elevated phosphorylated TBK1 (pTBK1), pIRF3, IKKε , and NF-κ B gene sets, and multiple secreted cytokines/chemokines (Fig. 1a,b and Supplementary Fig. 1b,c) . TBK1 activity was preferentially increased in additional mesenchymal SCLC cell lines ( Supplementary Fig. 1d ,e) and subpopulations of human and murine Rb L/L /p53 L/L SCLC tumors ( Fig. 1c and Supplementary  Fig. 1f-h) . Because H69M cells also attracted T cells and monocytes ( Supplementary Fig. 2a-e ), we explored immune checkpoint activation. This identified a PD-L1 high , CD44 high fibroblastic subpopulation responsible for pTBK1 and cytokine/chemokine production ( Fig. 1d-f and Supplementary Fig. 3a,b ).
H69M PD-L1 high cells reverted phenotypically in culture and were genomically similar to parental H69 cells ( Supplementary  Fig. 3c,d ), suggesting an epigenetic mechanism of innate immune activation. Since ERVs undergo epigenetic silencing, we examined expression of a recently described ERV panel 11, 12 . H69M-PD-L1 high cells exhibited marked upregulation of MLT1C49 (Fig. 1g) , an ERV poised to generate double-stranded RNA (dsRNA) due to antisense orientation in the 3′ untranslated region (UTR) of TRIM22, a STAT1 target gene 13 . Transfection of a 3′ UTR construct containing this antisense ERV was sufficient to induce cytokine and PD-L1 expression in H69M-PD-L1 low cells ( Fig. 1h and Supplementary Fig. 4a,b) , and in 293T cells ( Supplementary Fig 4c) . Conversely, siRNA-mediated knockdown of MLT1C49 partially inhibited CXCL10 and CCL2 expression in H69M-PD-L1 high cells ( Fig. 1i and Supplementary  Fig. 4d ), validating a direct role in this innate immune phenotype, but suggestive of redundancy.
Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses
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We therefore intersected all antisense 3′ UTR ERVs from RefSeq with H69M-upregulated genes (Supplementary Dataset 1) 9 , to identify additional ERV family members in this mesenchymal state with this unique genomic feature. This analysis identified TRIM22/ MLT1C49 and 14 other genes/ERVs, including TRIM38, which contained two (MLT1J, MLT1A), the majority of which were specifically induced in H69M-PD-L1 high cells ( Fig. 1j and Supplementary  Fig. 5a ). Similar to TRIM22, many of these genes contained STAT1 motifs and/or binding sites 13, 14 in their promoters ( Supplementary  Fig. 5b ), which suggested inducibility by the IFN-γ or other STAT1activating factors already present in H69M conditioned media (Fig. 1b,f) . Indeed, in contrast to H69 cells IFN-γ stimulation of the additional mesenchymal subpopulation, H69AR, induced expression of most, but not all, of these genes/ERVs, ( Supplementary  Fig. 5c ) validating a role for STAT1-mediated regulation. Conversely, IL32/THE1D and F3/MLT1I were inducible by IFN-γ in H69AR cells, but not upregulated in H69M-PD-L1 high cells ( Fig. 1j and Supplementary Fig. 5a,c ), suggesting some differences in transcriptional state between mesenchymal subclones. Regardless, these studies uncovered a wider set of genes with 3′ antisense ERVs preferentially expressed in the mesenchymal cell state and regulated by STAT1 signaling. Because of the unique ability of interferons to trigger their expression, create dsRNA via bi-directional transcription, and spark feed-forward innate immune signaling, we term these ERVs SPARCS.
ERV dsRNAs are sensed by the RIG-1/MDA5-MAVS signaling pathway or reverse-transcribed and detected via the cGAS-cGAMP STING pathway 15 . Indeed, we observed STING upregulation and increased cytoplasmic MLT1C49 dsDNA in H69M PD-L1 high cells ( Supplementary Fig. 5d -f). MAVS or combined MAVS/STING deletion in H69M cells strongly impaired TBK1 and IRF3 phosphorylation ( Fig.1k ), decreased multiple cytokines/chemokines, including CXCL10, CCL5, and CCL2 ( Fig. 1l,m) , and suppressed T cell and monocyte attraction ( Supplementary Fig. 6a,b ). Deletion of MAVS and/or STING also reverted the mesenchymal phenotype, increasing E-cadherin and decreasing Vimentin expression ( Fig. 1k and Supplementary Fig. 6c,d ). Thus, ERV sensing of SPARCS directly contributes to this cellular state.
IFN-γ also induced robust PD-L1 expression in H69AR cells, suggesting that differential chromatin accessibility could underlie this responsiveness ( Fig. 2a ). Indeed, even a 10 min IFN-γ pulse in H69AR, but not H69, cells resulted in marked induction of TRIM22 and MLT1C49, correlating with PD-L1 messenger RNA and cytokine/chemokine secretion (Fig. 2b,c and Supplementary Fig. 7a,b ). H69AR cells showed specific gain of chromatin accessibility around SPARCS loci, but not PD-L1, CXCL10, or CCL2 ( Fig. 2d and Supplementary Fig. 7c ). Because H69M and H69AR cells downregulated EZH2 16 (Fig. 2e ), we examined whether EZH2 is involved in silencing SPARCS. EZH2 inhibitor treatment of H69 cells over six days enhanced similar IFN-γ -induced cytokines (Fig. 2f) , and derepressed the same SPARCS as in H69AR cells ( Fig. 2g and Supplementary Fig. 7d ). Thus, SPARCS loci are normally silenced and protected from IFN-induced expression by EZH2, but derepressed in mesenchymal H69 subpopulations.
We next wondered whether SPARCS promote positive feedback signal amplification. We detected high levels of dsRNA preferentially produced from MLT1C49, MLT1J, and MLT1A in 10 min IFN-γ -pulsed H69AR cells, even after 24 h ( Fig. 2h ). TAGaided sense/antisense transcript detection PCR 17 confirmed that dsRNA resulted from bi-directional transcription of MLT1C49, MLT1J, and MLT1A ( Supplementary Fig. 8a ). IFN-γ pulse treatment activated and sustained pTBK1 and pIRF3 in addition to pSTAT1 in H69AR but not H69 cells ( Fig. 2i ), which further amplified SPARCS expression, pTBK1, and its effector cytokines over time ( Fig. 2j and Supplementary Fig. 8b,c) . Transfection of the dsRNA mimic Poly(I:C) induced type I/II IFNs in H69AR cells ( Supplementary Fig. 8d ) and direct IFN-α /β exposure or Poly(I:C) itself induced SPARCS ( Supplementary Fig. 8d ,e), consistent with positive feedback induced by dsRNA and type I IFN. Furthermore, exposure of untreated H69AR cells to IFN-γ primed conditioned medium activated TBK1 and STAT1 and induced CXCL10, IFNβ, and ERV expression ( Supplementary Fig. 9a-d) . These data confirmed feed-forward signaling downstream of SPARCS activation ( Supplementary Fig. 9e ). As expected, treatment with the JAK1/2 inhibitor ruxolitinib disrupted this circuit, whereas TBK1/IKKε inhibition with MRT67307 partially inhibited downstream CXCL10 expression ( Supplementary Fig 9f-h) . Finally, MAVS deletion also downregulated multiple cytokines/chemokines following Poly(I:C) or low-dose IFN-γ pulse treatment, especially when codeleted with STING ( Fig. 2k -m, Supplementary Fig. 9i,j) , and impaired tumorigenicity in nude mice ( Fig. 2n ).
To determine the broader relevance of SPARCS and to begin to explore the relationship to immune contexture, we next ranked expression of a signature comprised of the 15 SPARCS-containing genes across The Cancer Genome Atlas (TCGA) (Pancan12, n = 3,602 tumors) 18 using single-sample gene set enrichment analysis (ssGSEA) 19 ( Fig. 3a and Supplementary Fig. 10a,b ). Top gene sets co-enriched with SPARCS-containing genes (P < 0.01, false discovery rate (FDR) < 0.01) included epigenetic, TNF/NF-κ B, inflammation/innate immunity, and RTK/KRAS signaling ( Fig. 3a and Supplementary Dataset 2), also observed in the Cancer Cell Line Encyclopedia (CCLE) ( Supplementary Fig. 11a and Supplementary Dataset 2). In contrast, none of these signatures correlated with a control gene set derived by intersecting 3′ UTR antisense ERVs with H69M-downregulated genes ( Supplementary Fig. 11b and Supplementary Dataset 3). The SPARCS-high state also co-associated with mutations on chromosome 3p, including PBRM1 and SETD2, as well as oncogenic KRAS in CCLE ( Supplementary  Fig. 12a,b and Supplementary Dataset 4).
At the gene level, SPARCS-containing gene expression correlated with markers of T cell and myeloid infiltration uniquely in TCGA ( Supplementary Fig. 12c and Supplementary Dataset 2). In both CCLE and TCGA datasets SPARCS associated with expression of major histocompatibility complex (MHC), APOBEC, immune checkpoint, and EMT genes ( Supplementary Fig. 12c,d and Supplementary Dataset 2). Expression of EZH2, DNMT3A, SETD2, and multiple SWI/SNF genes inversely correlated with SPARCS ( Supplementary Fig. 12c,d and Supplementary Dataset 2). We next intersected the top 1,000 genes from TCGA and CCLE, to isolate robust cancer cell autonomous genes coregulated with SPARCS ( Fig. 3b and Supplementary Dataset 5). This identified B2M as the top-ranked gene, followed by multiple MHC class 1 genes 20 , cytosolic RNA sensors, and antigen-processing machinery, all markers of a virally infected state ( Fig. 3b and Supplementary Dataset 5). TGFB1 and AXL were also top hits ( Fig. 3b and Supplementary Dataset 5).
High expression of the SPARCS-containing gene signature in TCGA was enriched in distinct cancer histologies beyond SCLC, including clear cell renal, lung adenocarcinoma, head/neck squamous, and glioblastoma ( Fig. 3c ). SPARCS high CCLE lines also included triple-negative breast cancer (TNBC), and exhibited high relative expression of AXL, MET, VIM, TGFB1, and CD44, and low EZH2, SETD2, and SWI/SNF component expression ( Supplementary Fig. 13a and Supplementary Dataset 6). SPARCS high cell lines exhibited mesenchymal morphology and elevated AXL, MET, and Vimentin relative to SPARCS low cells ( Fig. 3d and Supplementary Fig. 13b ). Similar to the H69 model, SPARCS high cells exhibited increased STING, but not MAVS, levels ( Fig. 3d and Supplementary Fig. 13a ). IFN-γ pulse treatment of SPARCS high cells significantly induced MLT1C49, CXCL10, and PD-L1 expression relative to SPARCS low cells, and inducible surface PD-L1 correlated with high baseline CD44 expression ( Fig. 3e and Supplementary Fig. 14a ). 
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We next used immune cell gene set enrichment analysis 21 to assess whether certain immune infiltrates might be associated with elevated SPARCS-containing gene expression in TCGA ( Fig. 4a ). Despite markers of cytotoxic T cells and an adaptive immune response, the top associated signatures were innate immune response and myeloid derived suppressor cells, followed by 
TNFα 
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neutrophils and macrophages (Fig. 4a ). Grouping of TCGA tumors into discrete SPARCS high/low categories ( Supplementary Fig. 14b ) confirmed robust and significant association of SPARCS high tumors with these signatures (Fig. 4b,c) . Consistent with T cell and myeloid cell chemotaxis, CXCL10 and CCL2 gene expression in primary tumors was tightly associated with the SPARCS high state ( Fig. 4d and Supplementary Dataset 6). Thus, myeloid cell infiltration may further contribute to an immunosuppressed microenvironment in SPARCS high tumors.
Finally, we utilized ex vivo culture of patient-derived organotypic tumor spheroids (PDOTS) with autologous tumor infiltrating lymphocytes 22 to explore translational relevance of these findings. Using multiplexed immunofluorescence, we confirmed T cell infiltration of two different KRAS mutant non-small-cell lung cancer (NSCLC) specimens (Fig. 4e) , one with SPARCS high features including SETD2 inactivation and APOBEC mutation pattern (NSCLC-1), and the other with STK11/TP53 comutation (NSCLC-2) and T cell localization between tumor nests. IFN-γ or Poly(I:C) treatment of NSCLC-1 PDOTS markedly enhanced production of multiple cytokines/chemokines, especially CXCL10, and sensitized them to ex vivo PD-1 blockade with nivolumab, in contrast to NSCLC-2 ( Fig. 4f-h and Supplementary Fig. 14c-e ). Thus, IFN signaling associated with the SPARCS high state can be directly ascertained from patient samples and may promote sensitivity to PD-1 blockade.
Here, we identify SPARCS as a novel subclass of ERVs silenced by EZH2 and poised to undergo positive feedback signal amplification due to antisense localization in 3' UTRs of IFN-stimulated genes. Whereas prior reports utilized DNMT inhibition to uncover ERVs more generally to induce a state of viral mimicry 11, 12 , our data reveal that mesenchymal tumor subpopulations with high AXL/ MET expression and low EZH2 levels trigger expression of a specific set of ERVs when exposed to IFN-γ , with important implications for understanding tumor heterogeneity and oncogenesis. This SPARCS-high state was also associated with downregulation of multiple SWI/SNF components and enriched in renal cell carcinoma, potentially contributing to the immunogenicity recently reported following PBRM1 inactivation 23, 24 . While SPARCS expression promotes MHC class 1 upregulation and T cell infiltration, activation of immune checkpoints and myeloid infiltration may promote tumor immune suppression, similar to a chronic virally infected state. Therapeutically, this may have important implications for drug combinations with PD-1 blockade. For example, in addition to blocking specific chromatin regulators [23] [24] [25] , therapies that hyperactivate JAK signaling 26 or target TBK1 22,26 could alter SPARCS physiology to favor response.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41591-018-0116-5. Cell lines. The human SCLC cell lines NCI-H69, H69M, H69AR, NCI-H841, SHP77, NCI-H187, NCI-H345, and NCI-H524 were obtained from the laboratory of Dr. Joan Albanell and were authenticated following short tandem repeat (STR) genotyping. Clear cell renal cell carcinoma cell lines A704, A498, 786-O, 769-P, and Caki-2 were obtained from the laboratory of Dr. William G. Kaelin, Jr., and were authenticated following STR genotyping. HCC44 cell line was obtained from the Broad Institute and was authenticated following STR genotyping. Jurkat T cells, THP-1 monocytes, NCI-H196, MDA-MB-231, HCC1143, MDA-MB-468, NCI-H522, T47D, MDA-MB-453, NCI-H1436, NCI-H2081, and 293T cells were obtained from the American Type Culture Collection and used for all experiments before reaching 10 passages. All cells were routinely tested for mycoplasma and found to be free of contamination.
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Methods
H69, H69M, H69AR, H841, SHP77, H187, H345, H524, H196, HCC44, MDA-MB-231, MDA-MB-453, MDA-MB-468, T47D, HCC1143, H522, H1436, H2081, THP-1, Jurkat, and 769-P were cultured in RPMI-1640 (Thermo Fisher, no. 11875-119) containing 10% FBS (Gemini Bio-products, no. 100-106) and 1 × penicillin-streptomycin (Gemini Bio-Products, no. 400-109). 786-O, A498, and 293T were maintained in DMEM (Thermo Fisher, no. 11965-118) containing 10% FBS and 1 × penicillin-streptomycin. Caki-2 cells were maintained in McCoy's 5A medium (Life Technologies, no. 16600108) supplemented with 10% FBS and 1 × penicillin-streptomycin. A704 cell line was maintained in Eagle's Minimum Essential Medium (Sigma, no. M4780) supplemented with 2 mM Glutamine (Life Technologies, no. 25030081), 1% Non-Essential Amino Acids (Life Technologies, no. 11140-050), 1 mM sodium pyruvate (Life Technologies, no. 11360-070), 15% FBS, and 1 × penicillin-streptomycin.
Immunohistochemical staining. After deparaffinizing tissue blocks, antigen retrieval was achieved by wet autoclave (121 °C, 15 min) in Antigen Retrieval Solution, pH 9 (Dako, S2367), for p-TBK1. In order to block endogenous peroxide enzyme, tissue sections were incubated for 30 min using Peroxidase-Blocking Solution (Dako, S2023). Then, to block non-specific background staining, tissue sections were incubated for 20 min with Protein Block (Dako, X0909) (human tissue) or Mouse on Mouse blocking reagent (Vector Laboratories, MKB-2213) (mouse tissue). Primary antibody specific for pTBK1 (Cell Signaling Technology, 5483; 1:50 dilution) was applied, and slides were incubated for 16 h at 4 °C. Visualization was achieved using EnVision+ /HRP, Rabbit (Dako, K4003) for pTBK1, followed by diaminobenzidine (Dako, K3468) and hematoxylin counterstain. Expression levels of pTBK1 were evaluated by two pathologists who were blinded to other data.
SCLC genetically engineered mouse model. All mouse experiments were conducted in accordance with a Dana-Farber Cancer Institute Institutional Animal Care and Use Committee-approved protocol. Primary tumor and metastasis tissue sections used in this study were from the genetically engineered mouse model of SCLC consisting of the Rb L/L /p53 L/L allelic genotype 27 . A total number of 24 slices of 1 mm thickness were collected providing a sufficient number to cover the lung volume. Tumor volume per animal was quantified using a 3D Slicer by manual quantification of at least eight consecutive axial image sequences. Magnetic resonance imaging was performed to follow tumor volume and weights were monitored bi-weekly. Mice were euthanized and lungs and livers were perfused with 10% formalin, stored in fixative overnight, and embedded in paraffin. For further staining with H&E and antibodies, sections of 5 µ m were cut.
Immunoblotting, antibodies, and ELISA. Protein was isolated from cell lines and measured by BCA (Pierce Biotechnology). Protein extracts were subjected to polyacrylamide gel electrophoresis using the 4%-12% NuPAGE gel system (Invitrogen), transferred to PVDF (Millipore) membranes, and immunoblotted using antibodies that specifically recognize TBK1 (no. 3013), S172 pTBK1 (no. Secondary antibodies were from LICOR Biosciences: IRDye 800CW Goat anti-Mouse IgG (H+ L) (no. 926-32210) and IRDye 800CW Goat anti-Rabbit IgG (H+ L) (no. 926-32211). LICOR blocking buffer (no. 927-40000) was used to dilute primary and secondary antibodies, with the exception of phosho-specific antibodies, which were diluted in HIKARI Signal Enhancer Solutions 1 and 2 (Nacalai USA, Inc., no. NU00101). Imaging of blots and quantitation of bands was performed using the LICOR Odyssey system. Proteome Profiler Human Cytokine Array Kit (no. ARY005B) and CXCL10 ELISA (no. DIP100) (R&D Systems) were used according to manufacturer's instructions. For cytokine array, conditioned media from SCLC cells at basal conditions was collected after 48 and 72 h. For CXCL10 ELISA, conditioned media from IFN-γ -pulsed cells was collected after 72 h.
Microfluidic culture. Microfluidic device design and fabrication were performed as described 28 , with modifications of device dimensions to accommodate larger volumes of media. DAX-1 3D cell culture chip (AIM Biotech) was also used for select studies. H69, H69M, and H69AR cell suspensions (2.5 × 10 4 cells) were pelleted and resuspended in type I rat tail collagen (Corning) at a concentration of 2.5 mg ml −1 following addition of 10 × PBS with phenol red with pH adjusted using NaOH. pH 7.0-7.5 was confirmed using PANPEHA Whatman paper (Sigma-Aldrich). The cell-collagen mixture was then injected into the center gel region of the three-dimensional microfluidic culture device. Microfluidic culture devices were designed with a central region containing the cell-collagen mixture, surrounded by two media channels located on either side formed by bonding a coverslip to a patterned polydimethylsiloxane substrate. Collagen hydrogels containing cells were incubated for 30 min at 37 °C and then hydrated with media with or without 2.5 × 10 4 CFSE-labeled Jurkat T cells and THP1 monocytes in the side media channels. Jurkat T cells or THP1 monocytes were labeled with the CFSE Cell Division Tracker Kit (BioLegend) following manufacturer's instructions. Following 48 h of incubation, images were captured on a Nikon Eclipse 80i fluorescence microscope equipped with Z-stack (Prior) and CoolSNAP CCD camera (Roper Scientific). Image capture and analysis were performed using NIS-Elements AR software package. Whole device images were achieved by stitching in multiple captures. Cell quantitation was performed by measuring total cell area of CFSE dye.
Flow cytometry analysis and cell sorting. Cells were stained with anti-PD-L1 (BioLegend, catalog no. 329717), anti-CD44 (Biolegend, catalog no. 103011), or isotype IgG control antibodies (Biolegend, catalog no. 400326 and catalog no. 400611) in PBS containing 2% FBS for analysis and cell sorting. Briefly, cells were washed and further incubated with the indicated antibodies at 2 μ g ml −1 . After 3 washes with PBS, cells were resuspended in PBS containing 2% FBS and analyzed on a BD FACSCanto II or sorted to > 95% purity using a BD FACSAria II. Levels were compared with isotype control antibodies. PD-L1 and CD44 mean fluorescence intensity was normalized to isotype control. The data analyses were performed with FlowJo software (TreeStar).
Cytokine profiling. Multiplex assays were performed utilizing the bead-based immunoassay approach Bio-Plex Pro Human Cytokine 40-plex Assay (catalog no. 171AK99MR2) on a Bio-plex 200 system (catalog no. 171000201) (Bio-Rad Laboratories) and the Human Cytokine/Chemokine Magnetic Bead Panel (catalog no. HCYTMAG-60K-PX30) on a Luminex MAGPIX system (Merck Millipore). Conditioned media concentration levels (pg ml −1 ) of each protein were derived from five-parameter curve-fitting models. Fold changes relative to the corresponding control were calculated and plotted as log 2 (fold change) (log 2 FC). Lower and upper limits of quantitation were imputed from standard curves for cytokines above or below detection.
Quantitative PCR with reverse transcription (RT-qPCR). Total cellular RNA was extracted using the miRNeasy Mini Kit (Qiagen) according to manufacturer's instructions. After extraction, 1 μ g total RNA was used to generate cDNA with the SuperScript III First-Strand Synthesis SuperMix for RT-qPCR kit, which includes both oligo-dT and random primers (Thermo Fisher). RT-qPCR of the indicated genes ( Supplementary Dataset 7) was performed using SYBR green PCR Master Mix (Applied Biosystems) and the Applied Biosystems 7300 Fast real-time PCR system and software. The relative expression was normalized with the expression of the housekeeping gene 36B4. The sequences of primers used have been listed in Supplementary Dataset 7.
Nuclear/cytoplasmic fractionation and DNA purification. Nuclear/cytoplasmic fractions from H69M PD-L1 low and H69M PD-L1 high cells were obtained according to the manufacturer's instructions (Nuclear/Cytosol Fractionation Kit, no. K266-25, BioVision). Cleared extracts were treated with 20 mg ml −1 RNase A (Qiagen) for 30 min at 37 °C, 20 mg ml −1 Proteinase K (Thermo Fisher) for 1 h at 55 °C, and then extracted with phenol:chloroform (Invitrogen). DNA was isopropanol precipitated, washed with 70% Ethanol, air-dried, and resuspended in water.
Digital droplet PCR. PCR reactions (25 μ l) that comprised ddPCR Supermix for Probes, custom-made Taqman primer/probe mix, and appropriate DNA template were prepared in a 96-well PCR plate and subsequently loaded onto the Automated Droplet Generator (Bio-Rad). After droplet generation, the new 96-well PCR plate was heat-sealed, placed on a conventional thermal cycler, and amplified to the end-point. After PCR, the 96-well PCR plate was read on the QX100 droplet reader (Bio-Rad). Analysis of the ddPCR data was performed with QuantaSoft analysis software (Bio-Rad) that accompanied the droplet reader. The sequences of primers used have been listed in Supplementary Dataset 7.
ERV over-expression and knockdown. The 3′ UTR TRIM22 region including the antisense MLT1C49 ERV was amplified with PCR from H69M cell RNA and cloned into pLX_307 vector. H69M PD-L1 low cells were transfected by nucleofection (Amaxa 4D-Nucleofector X Unit) according to the manufacturer's instructions (Lonza). RNA was isolated after 24 h and conditioned media after 72 h postnucleofection with this construct versus pLX 307-GFP. 293T cells, which lack STING, were transduced with these same constructs using X-treme Gene 9 (Roche) according to the manufacturer's instructions, followed by isolation of both RNA and conditioned media after 72 h to maximize sensitivity.
For knockdown experiments, H69M PD-L1 high cells were transfected with a scrambled negative control siRNA or two siRNAs targeting MLT1C49 (each 40 nM) using Lipofectamine RNAiMAX Reagent (Thermo Fisher). RNA was isolated after 72 h post-transfection to ensure knockdown.
CRISPR-Cas9 gene editing and lentiviral infection.
Oligonucleotides coding for guide RNAs that target STING and MAVS genes were chosen from the Avana library and the Brunello library 29 . A non-targeting single guide RNA (sgRNA) from the Gecko library v2 was used as a dummy sgRNA for control 30 . Lenti CRISPRv2 vectors were cloned as previously described 30, 31 . sgRNA target sequences are described in Supplementary Dataset 7.
293T cells were transduced with lentiCRISPRv2 using X-treme Gene 9 (Roche) according to the manufacturer's instructions. On day two, target cells were seeded, and allowed to adhere overnight. On day three, the supernatant of transduced 293T cells was collected and added to the target cells through a 0.45-μ m filter. Supernatant from transduced 293T cells was again collected and added to target cells on day four. On day five, puromycin or blasticidin was added to select infected cells (for four days).
Compounds and treatments.
Recombinant human IFN-γ (no. 285-IF), IFN-α (no. 11100-1), and IFN-β (no. 8499-IF) proteins were purchased from R&D Systems and reconstituted in sterile, deionized water. MRT67307 and ruxolitinib were synthesized and purchased from Shanghai Haoyuan Chemexpress Co. Both drugs were reconstituted at 10 mM in DMSO and stored at − 20 °C. GSK126 (no. S7061) was purchased from Selleck chemicals and reconstituted at 5 mM in DMSO and stored at − 20 °C.
For IFN pulse experiments, cells were pulsed for 10 min with IFN-γ (200 ng ml −1 or 10 ng ml −1 ), IFN-α (10,000 unit (U) ml −1 ), or IFN-β (10,000 U ml −1 ), extensively washed, and chased in fresh media for an additional 24, 48, or 72 h. To test drug effects on gene expression or protein secretion, IFN-γ pulsed H69AR cells were treated with DMSO, 1 μ M MRT67307, or 100 nM ruxolitinib for 24, 48, and 72 h.
For EZH2 inhibition experiments, H69 cells were treated with 5 μ Μ GSK126 for 6 d. Drug was replenished every three days with both suspension and adherent cells carried each time. After the GSK126 treatment period, equal numbers of DMSO-treated and GSK126-treated cells were exposed to either H 2 O or 200 ng ml −1 IFN-γ for 24 h before harvesting of RNA or conditioned media. dsRNA enrichment. For dsRNA enrichment, RNA was first treated or not for 30 min with 50 μ g ml −1 RNase A (Qiagen) in high salt concentration (NaCl, 0.35 M) to prevent dsRNA degradation. After treatment, RNase A was removed by ethanol precipitation and the product was resuspended in sterile water. Next, RNase A-treated RNA was immunoprecipitated using the J2 dsRNA-specific antibody (English and Scientific Consulting Kft.). In brief, the product of 9 μ g RNase A-treated RNA was incubated in binding buffer (150 mM NaCl, 50 mM TRIS pH 8.0, 1 mM EDTA, 1% NP-40) with 5 μ g J2 antibody, rotating overnight at 4 °C. J2-bound dsRNA was incubated in binding buffer with 25 μ l Dynabeads Protein G (Thermo Fisher) for 4 h at 4 °C, followed by 5 washes in cold binding buffer. RNA was then extracted with TRIzol Reagent and expression levels of indicated genes were analyzed by RT-qPCR.
Enrichment of dsRNA over single-stranded RNA was then calculated by normalizing the delta Ct of ERVs (dsRNA) against beta-actin (single-stranded RNA).
First-strand cDNA synthesis and strand-specific PCR for detection of sense and antisense ERV transcripts using TAG-aided sense/antisense transcript detection methodology. Components from the SuperScript III First-Strand
Synthesis System for reverse transcription-PCR (RT-PCR) (Thermo Fisher) were adapted to perform reverse transcription with RNA from H69AR previously pulsed with IFN-γ for 10 min. For first-strand cDNA synthesis, 400 ng RNA was used for ß-actin, MLT1C49, MLT1A, and MLT1J. A gene-specific primer (1 μ M) ligated to a TAG sequence not specific for the human genome (GSP sense/antisense (RT) TAG) was implemented in the reaction. RNA and primers were preheated at 65 °C for 5 min. For the total reaction: the GSP-TAG, 0.5 mM dNTP, 5 mM MgCl2, 10 mM DTT, 40 U RNaseOUT, 100 U SuperScriptIII RT, and 240 ng Actinomycin D (Sigma-Aldrich) were added with the RNA for a 20 μ l reaction. Synthesis was performed at 50 °C for 50 min and terminated at 85 °C for 5 min. RT with extremely low intrinsic RNase H activity (for cleavage of RNA from RNA-DNA duplexes) and Actinomycin D was added to prevent second-strand cDNA RT resulting in antisense artifacts 32 . After cDNA synthesis 2 U recombinant RNase H was added to each reaction and incubated for 20 min at 37 °C. Finally, the first strand cDNA mix was ethanol precipitated and resuspended in 10 μ l sterile water. Afterwards, gene-and strand-specific RT-qPCR was performed using SYBR green PCR Master Mix. To amplify sense cDNA and antisense cDNA a TAG-primer and GSP senseprimer and a TAG-primer and GSP antisense-primer were used, respectively. We performed sense-and antisense-specific RT-qPCR using both sense and antisense cDNA of beta-actin as an internal negative control that was previously demonstrated to have no antisense transcript 33 . The sequences of primers used have been listed in Supplementary Dataset 7.
Poly(I:C) treatment. For Poly(I:C) dsRNA treatment experiments, H69ARsgCTRL and H69ARsgMAVS cells were plated in RPMI media, transfected with 0.5 μ g ml −1 Poly(I:C) HMW (InvivoGen) using XtremeGene HP transfection reagent (Sigma-Aldrich), and cultured for 72 h. On day three after transfection, conditioned media was recovered and CXCL10 protein expression was quantified using Human CXCL10/IP-10 Quantikine ELISA kit (R&D Systems). RNA was extracted and expression levels of relevant genes were analyzed by RT-qPCR.
Xenograft studies. H69AR xenograft model was established by subcutaneous injection of 2.5 × 10 5 sgCTRL or sgMAVS-H69AR cells in matrigel (Corning) into the flank of nude mice (Charles River Laboratories). Tumor volume was determined from caliper measurements of tumor length (L) and width (W), according to the formula L× W 2 /2. Both tumor size and body weight were measured three times per week.
Multiplexed immunofluorescence. Multiplex immunofluorescent staining was performed overnight for approximately 12 h on BOND RX fully automated stainers (Leica Biosystems), as previously described 34 . Briefly, tissue sections of 5-μ m thick formalin-fixed, paraffin-embedded (FFPE) were baked for 3 h at 60 °C before loading into the BOND RX. Slides were deparaffinized (BOND DeWax Solution, Leica Biosystems) and rehydrated with series of graded ethanol to deionized water. Antigen retrieval was performed in BOND Epitope Retrieval Solution 1 (ER1, Leica Biosystems) at pH 6 for 10 min at 98 °C. Deparaffinization, rehydration, and antigen retrieval were all preprogrammed and executed by the BOND RX. Next, slides were serially stained with primary antibodies, such as anti-CD8 (clone C8/144B, DAKO; dilution 1:5,000). Incubation time per primary antibody was 40 min. Subsequently, anti-rabbit Polymeric Horseradish Peroxidase (Poly-HRP, BOND Polymer Refine Detection Kit, Leica Biosystems) was applied as a secondary label with an incubation time of 10 min. Signal for antibody complexes was labeled and visualized by their corresponding Opal Fluorophore Reagents (PerkinElmer) by incubating the slides for 5 min. The same process was repeated for the corresponding antibodies/fluorescent dyes ( Supplementary Table 1 ). Slides were air dried, mounted with Prolong Diamond Anti-fade mounting medium (no. P36965, Life Technologies), and stored in a light-proof box at 4 °C before imaging. The target antigens, antibody clones, and dilutions for markers included in this report and details of controls are listed in Supplementary Table 1 .
Image acquisition and analysis. Image acquisition was performed using the Mantra multispectral imaging platform (Vectra 3, PerkinElmer), as previously described 34 . Areas with non-tumor or residual normal tissue (that is, residual lymph node) were excluded from the analysis. Representative regions of interest were chosen by the pathologist, and 5-7 fields of view were acquired at × 20 resolution as multispectral images. Image Analysis was performed using the Inform 2.3 Image Analysis Software (PerkinElmer).
Ex vivo culture of PDOTS. PDOTS from human NSCLC resection specimens were generating according to our recent publication 22 . Briefly, fresh tumor specimens were minced and resuspended in media with collagenase type IV (Life Technologies). After digestion, samples were strained over 100-μ m filters and 40-μ m filters to generate S1 (> 100 μ m), S2 (40-100 μ m), and S3 (< 40 μ m) spheroid fractions. S2 spheroid fraction was pelleted and resuspended in type I rat tail collagen (Corning) at a concentration of 2.5 mg ml −1 . The spheroid-collagen mixture was then injected into the center gel region of the three-dimensional microfluidic culture device. Collagen hydrogels containing PDOTS were hydrated with media and treated with anti-PD-1 (Nivolumab, 100 μ g ml −1 ), IFNγ (200 ng ml −1 ), Poly (I:C) (0.5 μ g ml −1 ), or combination (Nivolumab + IFN-γ , Nivolumab + Poly (I:C)). The number of live/dead cells in each treatment condition was determined by the Trypan Blue Exclusion method and plotted as percentage of viability. Nivolumab (Opdivo; Bristol-Myers Squibb) was obtained from the Dana-Farber Cancer Institute pharmacy.
OncoPanel assay. Somatic mutations, copy number variations, and structural variants in parental H69 cells and H69M-PD-L1 low /H69M-PD-L1 high subpopulations were evaluated by performing the OncoPanel assay from the Center for Advanced Molecular Diagnostics from Brighman and Women's Hospital.
This OncoPanel assay surveys exonic DNA sequences of 300 cancer genes and 113 introns across 35 genes for rearrangement detection. DNA was isolated from cell lines and analyzed by massively parallel sequencing using a solution-phase Agilent SureSelect hybrid capture kit and an Illumina HiSeq 2500 sequencer. 
Data exclusions
Describe any data exclusions. No data were excluded from the analyses
Replication
Describe whether the experimental findings were reliably reproduced.
All attemps of replication were successful
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Upon detection of tumor growth mice were randomized into treatment groups and treated with indicated drugs, as described in Ref. 27 
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Expression levels of pTBK1 immunohistochemical staining in human and mice tumor samples and multiplexed immunofluorescence staining in NSCLC specimens were evaluated by two pathologists who were blinded to other data.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance. For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
Limited number of SCLC human and mouse tumor slices for IHC staining and limited NSCLC human slices for multiplexed immunofluorescence
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).
We used antibodies that specifically recognize TBK1 (#3013), S172 pTBK1 (#5483), pERK1/2 (#4370), ERK1/2 (#9107), S473 pAKT (#4060), AKT (#9272), S396 pIRF3 (#4947), IRF3 (#4302), Y701 pSTAT1 (#9171), STAT1 (#9172), AXL (#8661), EZH2 (#5246), STING (#13647), MAVS (#3993), E-Cadherin (#3195), Vimentin (#5741), beta-Actin (#4970), Tubulin (#2144), Lamin A/C (#2032) (Cell Signaling Technologies, Danvers, MA) and IKKepsilon (#I4907) (Sigma-Aldrich, St. Louis, MO). All the antibodies were previously validated by the manufacturer (online at Cell Signaling Technologies and Sigma-Aldrich websites). Information about antibodies used for multiplexed IF is available in Supplementary Table 1 c. Report whether the cell lines were tested for mycoplasma contamination.
All cell lines tested negative for mycoplasma contamination d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by ICLAC, provide a scientific rationale for their use.
No commonly misidentified cell lines were used
